Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.

The treatment cost per year to achieve a relapse-free patient was stable during successive measurements in the same population. Therefore, it may be considered a good real-world health indicator for patients with RRMS treated with DMTs.